(function(){var loadHandler=window['sl_{F297F516-7A70-460A-8CEB-C9E684C52205}'];loadHandler&&loadHandler(9, '<div id="spr0_3cafa5"><div id="spr1_3cafa5" class="kern slide"><img id="img1_3cafa5" src="data/img2.png" width="1280px" height="720px" alt="" style="left:0px;top:0px;"/><img id="img0_3cafa5" src="data/img0.png" width="1280.013" height="720" alt="" style="left:0.153px;"/></div><div id="spr2_3cafa5" class="kern slide"><div id="spr3_3cafa5" style="left:127.867px;top:28.833px;"><div style="width:0px;"><span id="txt0_3cafa5" data-width="665.338501" style="left:9.603px;top:10.368px;">OUTCOME MEASUREMENT</span></div></div><div id="spr4_3cafa5" style="left:127.867px;top:118.083px;"><div style="width:0px;"><span id="txt1_3cafa5" class="relpos" data-width="329.730469" style="left:9.603px;top:1.562px;">Outcomes for effectiveness:Â </span> <span id="txt2_3cafa5" class="relpos" data-width="371.285156" style="left:9.596px;top:2.065px;">Key clinical outcomes from trials</span></div><div style="width:0px;"><span id="txt3_3cafa5" class="nokern relpos" dir="auto" style="left:24.273px;top:44.148px;">-</span> <span id="txt4_3cafa5" class="relpos" data-width="785.683594" style="left:51.397px;top:38.044px;">Primary: Lung function (FEV1) and decline in lung function over time</span></div><div style="width:0px;"><span id="txt5_3cafa5" class="nokern relpos" dir="auto" style="left:24.273px;top:70.624px;">-</span> <span id="txt6_3cafa5" class="relpos" data-width="800.144531" style="left:51.397px;top:64.519px;">Secondary: number of pulmonary exacerbations and hospitalisations</span></div><div style="width:0px;"><span id="txt7_3cafa5" data-width="248.589844" style="left:9.603px;top:126.025px;">Outcomes for utilities:</span></div><div style="width:0px;"><span id="txt8_3cafa5" class="nokern relpos" dir="auto" style="left:24.273px;top:169.162px;">-</span> <span id="txt9_3cafa5" class="relpos" data-width="624.714844" style="left:51.397px;top:163.057px;">Generic HRQoL measures: EQ-5D-5L, HUI, SF-36 (SF-6D)</span></div><div style="width:0px;"><span id="txt10_3cafa5" class="nokern relpos" dir="auto" style="left:24.273px;top:195.637px;">-</span> <span id="txt11_3cafa5" class="relpos" data-width="740.074219" style="left:51.397px;top:189.532px;">Disease specific HRQoL measure: CFQ-R (mapping to EQ-5D-5L)</span></div><div style="width:0px;"><span id="txt12_3cafa5" class="nokern relpos" dir="auto" style="left:24.273px;top:221.557px;">-</span> <span id="txt13_3cafa5" class="relpos" data-width="884.917969" style="left:51.397px;top:215.452px;">Disutility values for acute CF lung exacerbations and reduced lung capacity</span></div><div style="width:0px;"><span id="txt14_3cafa5" data-width="938.484375" style="left:9.603px;top:277.404px;">Instruments for outcomes: EQ-5D-5L, Danish tariff for calculating (no Latvian tariffs</span></div><div style="width:0px;"><span id="txt15_3cafa5" data-width="117.726563" style="left:9.603px;top:303.879px;">available)</span></div></div></div></div>', '{"s":[]}');})();